Last reviewed · How we verify
IFO
Ifosfamide is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis.
IFO, also known as Ifosfamide, is an alkylating agent used primarily in the treatment of various cancers, particularly sarcomas. Developed by the Italian Sarcoma Group, it is not approved by the FDA and lacks a formal FDA label. The drug works by cross-linking DNA, which inhibits cell replication and leads to cell death. Common side effects include nausea, vomiting, and bone marrow suppression. Despite its efficacy, IFO has significant toxicity concerns, particularly nephrotoxicity and neurotoxicity.
At a glance
| Generic name | IFO |
|---|---|
| Also known as | Ifosfamide |
| Sponsor | Italian Sarcoma Group |
| Drug class | Alkylating Agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Ifosfamide exerts its cytotoxic effects by forming covalent bonds with DNA, leading to the formation of interstrand and intrastrand cross-links, which disrupt DNA replication and transcription.
Approved indications
- Testicular Germ Cell Tumor
Pipeline indications
Common side effects
- Nausea
- Vomiting
- Bone Marrow Suppression
- Nephrotoxicity
- Neurotoxicity
Drug interactions
- Mesna (reduces urotoxicity)
- Cisplatin (increased nephrotoxicity)
Key clinical trials
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (PHASE2, PHASE3)
- CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL (PHASE3)
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- LBL-2016 for Children or Adolescents in China (PHASE3)
- Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (PHASE3)
- Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IFO CI brief — competitive landscape report
- IFO updates RSS · CI watch RSS
- Italian Sarcoma Group portfolio CI